Board Change
Updated : 07:00
25 August 2021
Clinigen Group plc
Board Change
Clinigen Group plc (AIM: CLIN) ('Clinigen' or the 'Company' or the 'Group'), the global pharmaceutical Products and Services company, announces that Nick Keher will be stepping down as a Director of the Company with immediate effect, and as Chief Financial Officer following a handover, to pursue other business interests.
Richard Paling, the Group's Financial Controller since April 2017, will assume the role of interim Chief Financial Officer and an external search for a new, permanent Chief Financial Officer is underway.
Shaun Chilton, Chief Executive Officer of Clinigen, said: "I would like to thank Nick both personally and on behalf of the Clinigen team for his dedicated work for the Company over the past two and a half years. Nick has played a pivotal role in helping us to deliver on our ambitious strategy against the backdrop of the global COVID-19 pandemic and we wish him every success in the future."
Nick Keher, outgoing Chief Financial Officer, said: "Clinigen is an exceptional company and it has been a pleasure working with the Clinigen Board and the wider Clinigen team. I look forward to watching the Company continue to grow and deliver value to patients, customers and shareholders."
- Ends -
Contact details
Clinigen Group plc | +44 (0) 1283 495010 |
Shaun Chilton, Chief Executive Officer Rob Fox, VP Investor Relations and Corporate Development | |
|
|
Numis Securities Limited - Nominated Adviser & Joint Broker | Tel: +44 (0) 20 7260 1000 |
James Black / Garry Levin / Freddie Barnfield |
|
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas |
|
|
|
Consilium Strategic Communications Mary-Jane Elliott / Matthew Cole / Jessica Hodgson | Tel: +44 (0) 20 3709 5700 Clinigen@consilium-comms.com
|
|
|
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.
Clinigen has more than 1,000 employees across five continents in 16 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 115 countries.
For more information on Clinigen, please visit http://www.clinigen.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.